RT Journal Article
SR Electronic
T1 Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 lineages
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.01.21259859
DO 10.1101/2021.07.01.21259859
A1 Petrone, Mary E.
A1 Rothman, Jessica E.
A1 Breban, Mallery I.
A1 Ott, Isabel M.
A1 Russell, Alexis
A1 Lasek-Nesselquist, Erica
A1 Kelly, Kevin
A1 Omerza, Greg
A1 Renzette, Nicholas
A1 Watkins, Anne E.
A1 Kalinich, Chaney C.
A1 Alpert, Tara
A1 Brito, Anderson F.
A1 Earnest, Rebecca
A1 Tikhonova, Irina R.
A1 Castaldi, Christopher
A1 Kelly, John P.
A1 Shudt, Matthew
A1 Plitnick, Jonathan
A1 Schneider, Erasmus
A1 Murphy, Steven
A1 Neal, Caleb
A1 Laszlo, Eva
A1 Altajar, Ahmad
A1 Pearson, Claire
A1 Muyombwe, Anthony
A1 Downing, Randy
A1 Razeq, Jafar
A1 Niccolai, Linda
A1 Wilson, Madeline S.
A1 Anderson, Margaret L.
A1 Wang, Jianhui
A1 Liu, Chen
A1 Hui, Pei
A1 Mane, Shrikant
A1 Taylor, Bradford P.
A1 Hanage, William P.
A1 Landry, Marie L.
A1 Peaper, David R.
A1 Bilguvar, Kaya
A1 Fauver, Joseph R.
A1 Vogels, Chantal B.F.
A1 Gardner, Lauren M.
A1 Pitzer, Virginia E.
A1 George, Kirsten St.
A1 Adams, Mark D.
A1 Grubaugh, Nathan D.
YR 2021
UL http://medrxiv.org/content/early/2021/07/02/2021.07.01.21259859.abstract
AB Emerging SARS-CoV-2 variants have shaped the second year of the COVID-19 pandemic and the public health discourse around effective control measures. Evaluating the public health threat posed by a new variant is essential for appropriately adapting response efforts when community transmission is detected. However, this assessment requires that a true comparison can be made between the new variant and its predecessors because factors other than the virus genotype may influence spread and transmission. In this study, we develop a framework that integrates genomic surveillance data to estimate the relative effective reproduction number (Rt) of co-circulating lineages. We use Connecticut, a state in the northeastern United States in which the SARS-CoV-2 variants B.1.1.7 and B.1.526 co-circulated in early 2021, as a case study for implementing this framework. We find that the Rt of B.1.1.7 was 6-10% larger than that of B.1.526 in Connecticut in the midst of a COVID-19 vaccination campaign. To assess the generalizability of this framework, we apply it to genomic surveillance data from New York City and observe the same trend. Finally, we use discrete phylogeography to demonstrate that while both variants were introduced into Connecticut at comparable frequencies, clades that resulted from introductions of B.1.1.7 were larger than those resulting from B.1.526 introductions. Our framework, which uses open-source methods requiring minimal computational resources, may be used to monitor near real-time variant dynamics in a myriad of settings.Competing Interest StatementN.D.G. is a paid consultant for Tempus Labs to develop infectious disease diagnostic assays. K.S.G. receives research support from Thermo Fisher for the development of assays for the detection and characterization of viruses. All other authors declare no competing interests.Funding StatementThis work was funded by CTSA Grant Number TL1 TR001864 (M.E.P. and T.A.), Fast Grant from Emergent Ventures at the Mercatus Center at George Mason University (N.D.G.) and CDC Contract # 75D30120C09570 (N.D.G.). Initial funding for sequencing at the Wadsworth Center was provided by the New York Community Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board from the Yale University Human Research Protection Program determined that the RT-qPCR testing and sequencing of de-identified remnant COVID-19 clinical samples obtained from clinical partners conducted in this study is not research involving human subjects (IRB Protocol ID: 2000028599). The Institutional Review Board of The Jackson Laboratory determined that use of de-identified residual COVID-19 clinical samples obtained from the Clinical Genomics Laboratory for RT-qPCR testing and sequencing for this study is not research involving human subjects (IRB Determination: 2020-NHSR-021). Residual portions of respiratory specimens from individuals who tested positive for SARS-CoV-2 by RT-PCR were obtained from the Wadsworth Center and partnering clinical laboratories. This work was approved by the New York State Department of Health Institutional Review Board, under study numbers 02-054 and 07-022.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll of the genomic data used for the analyses in this manuscript are available on GISAID (gisaid.org). We gratefully acknowledge all of the laboratories that obtained the clinical specimen and generated the SARS-CoV-2 genomes used in our analyses (acknowledgment tables included in supplement). All files associated with our phylogenetic analysis may be found in our Github repository (https://github.com/grubaughlab/paper_2021_B117vsB1526). https://github.com/grubaughlab/paper_2021_B117vsB1526